Table 2.
Patient Characteristics
| Glioblastoma | Astrocytoma | Diffuse Glioma | |
|---|---|---|---|
| n | 435 | 39 | 9 |
| Sex = male (%) | 271 (62.3) | 18 (46.2) | 5 (55.6) |
| Age (median [range]) | 61 [18, 89] | 39 [23, 68] | 35 [18, 53] |
| MGMT methylation status (%) | |||
| Methylated | 191 (43.9) | 31 (81.6) | 1 (11.1) |
| NA | 1 (0.2) | 0 (0.0) | 1 (11.1) |
| Performance status (%) | |||
| 0–1 | 401 (92.6) | 37 (94.9) | 8 (88.9) |
| 2 | 27 (6.2) | 0 (0.0) | 1 (11.1) |
| 3–4 | 3 (0.7) | 0 (0.0) | 0 (0.0) |
| NA | 2 (0.5) | 2 (5.1) | 0 (0.0) |
| Corticosteroid use (%) | |||
| No | 244 (56.2) | 29 (74.4) | 4 (44.4) |
| Yes | 190 (43.8) | 9 (23.1) | 4 (44.4) |
| NA | 0 (0.0) | 1 (2.6) | 1 (11.1) |
| Extent of resection (%) | |||
| Macrototal resection | 254 (58.5) | 25 (64.1) | 2 (22.2) |
| Partial resection | 95 (21.9) | 10 (25.6) | 3 (33.3) |
| Stereotactic biopsy | 84 (19.4) | 4 (10.3) | 4 (44.4) |
| NA | 1 (0.2) | 0 (0.0) | 0 (0.0) |
| First-line treatment (%) | |||
| Standard therapy | 375 (86.2) | 28 (71.8) | 6 (66.7) |
| Standard therapy variations | 21 (4.8) | 0 (0.0) | 0 (0.0) |
| 3 Gy × 10 only | 16 (3.7) | 0 (0.0) | 1 (11.1) |
| Standard therapy + trial drug | 10 (2.3) | 0 (0.0) | 0 (0.0) |
| 2 Gy × 30 only | 6 (1.4) | 0 (0.0) | 1 (11.1) |
| Temozolomide only | 5 (1.1) | 8 (20.5) | 0 (0.0) |
| Other | 2 (0.5) | 3 (7.7) | 1 (11.1) |
| Completed standard therapy (%) | |||
| No | 223 (59.6) | 6 (21.4) | 4 (66.7) |
| Yes | 129 (34.3) | 21 (75.0) | 2 (33.3) |
| In treatment | 23 (6.1) | 1 (3.6) | 0 (0.0) |
| Genomic analysis (%) | |||
| WGS | 246 (56.6) | 19 (48.7) | 3 (33.3) |
| WES | 177 (40.7) | 18 (46.2) | 4 (44.4) |
| Targeted panel | 12 (2.8) | 2 (5.1) | 2 (22.2) |
| Relapse surgery = yes (%) | 166 (45.9) | 9 (34.6) | 2 (25.0) |
MGMT = O6-methylguanine-DNA methyltransferase; SD = standard deviation.
Corticosteroids are whether patients received 10 mg at the first meeting with the oncologist. Extent of resection is as judged by the surgeon. Regarding treatment (1) standard therapy + trial drug: 10 patients had extra treatment added on to their standard therapy as part of a clinical trial (5 nivolumab or placebo, 4 trotabresib, and 1 marizomib). (2) Standard therapy variations include 4 patients who received 2 Gy × 30 but nivolumab instead of temozolomide, 15 patients received 3 Gy × 10 only but also adjuvant temozolomide, 3 patients received regular standard therapy but nontargeted immunotherapy instead of the adjuvant temozolomide, and 1 patient received 2 Gy × 30 only and adjuvant temozolomide. (3) Other includes single patients receiving bevacizumab/irinotecan, bevacizumab/nivolumab, lomustine, NTRK-inhibitor, and 2 untreated patients. Regarding genomic analysis, targeted panel includes TSO500 and archers Fusionplex.